Show simple item record

Depositordc.contributorMcCulloch, Laura
Funderdc.contributor.otherBBSRC - Biotechnology and Biological Sciences Research Councilen_UK
Funderdc.contributor.otherMRC - Medical Research Councilen_UK
Funderdc.contributor.otherUniversity of Edinburghen_UK
Spatial Coveragedc.coverage.spatialUKen
Spatial Coveragedc.coverage.spatialUNITED KINGDOMen
Data Creatordc.creatorMcCulloch, Laura
Date Accessioneddc.date.accessioned2019-05-17T08:57:36Z
Date Availabledc.date.available2019-05-17T08:57:36Z
Citationdc.identifier.citationMcCulloch, Laura. (2019). Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence, [dataset]. UK Dementia Research Institute at the University of Edinburgh. https://doi.org/10.7488/ds/2552.en
Persistent Identifierdc.identifier.urihttp://hdl.handle.net/10283/3332
Persistent Identifierdc.identifier.urihttps://doi.org/10.7488/ds/2552
Dataset Description (abstract)dc.description.abstract## This item has been replaced by the one which can be found at http://hdl.handle.net/10283/3354 ## Full datasets for all figures in the manuscript "Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence". ## ABSTRACT ## ### Background ### Blockade of the cytokine interleukin-1 (IL-1) with IL-1 receptor antagonist (IL-1Ra) is a candidate treatment for stroke entering phase II/III trials, which acts by inhibiting harmful inflammatory responses. Infection is a common complication after stroke that significantly worsens outcome and is related to stroke-induced deficits in systemic immune function thought to be mediated by the sympathetic nervous system. Therefore, immunomodulatory treatments for stroke, such as IL-1Ra, carry a risk of aggravating stroke-associated infection. Our primary objective was to determine if factors associated with antibody-mediated antibacterial defences were further compromised in patients treated with IL-1Ra after stroke. ### Methods ### We assessed plasma concentrations of immunoglobulin isotypes and complement components in stroke patients treated with IL-1Ra or placebo and untreated non-stroke controls using multiplex protein assays. Activation of the SNS was determined by measuring noradrenaline, a major SNS mediator. ### Results ### There were significantly lower plasma concentrations of IgM, IgA, IgG1 and IgG4 in stroke-patients compared to non-stroke controls, however there were no differences between stroke patients treated with placebo or IL-1Ra. Concentrations of complement components associated with the classical pathway were increased and those associated with the alternative pathways decreased in stroke patients, neither being affected by treatment with IL-1Ra. Noradrenaline concentrations were increased after stroke in both placebo and IL-1Ra-treated stroke patients compared to non-stroke controls. ### Conclusion ### These data show treatment with IL-1Ra after stroke does not alter circulating immunoglobulin and complement concentrations and is therefore unlikely to further aggravate stroke-associated infection susceptibility through reduced availability of these key anti-microbial mediators.en_UK
Dataset Description (TOC)dc.description.tableofcontentsFiles are included in ".pzf" format (GraphPad Prism) and, to provide accessibility for users who do not have GraphPad Prism, copies of all data are also provided in Excel format ".xlsx".en_UK
Languagedc.language.isoengen_UK
Publisherdc.publisherUK Dementia Research Institute at the University of Edinburghen_UK
Relation (Is Referenced By)dc.relation.isreferencedbyhttps://www.biorxiv.org/content/10.1101/587881v2en_UK
Relation (Is Referenced By)dc.relation.isreferencedbyInterleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence Laura McCulloch, Stuart M. Allan, Craig J. Smith, Barry W. McColl bioRxiv 587881; doi: https://doi.org/10.1101/587881en_UK
Superseded Bydc.relation.isreplacedbyhttp://hdl.handle.net/10283/3354
Rightsdc.rightsCreative Commons Attribution 4.0 International Public Licenseen
Subjectdc.subjectstrokeen_UK
Subjectdc.subjectIL-1Raen_UK
Subjectdc.subjectimmunoglobulinsen_UK
Subjectdc.subjectcomplementen_UK
Subjectdc.subjectinfectionen_UK
Subject Classificationdc.subject.classificationBiological Sciencesen_UK
Titledc.titleSUPERSEDED - Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defenceen_UK
Typedc.typedataseten_UK

Download All
zip file MD5 Checksum: 5d2eaf5b74656f1878eb50a0416a20d2

Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record